Share Prices & Company Research

Market News

08 Apr 2021 | 12:48

Cambridge Cognition wins at-home clinical trial contract

(Sharecast News) - Brain health technology company Cambridge Cognition has won a contract with a new pharmaceutical client to provide cognitive assessments in an at-home clinical trial, it announced on Thursday. The AIM-traded firm said the contract was worth around £0.5m, with most of the revenue to be recognised in 2021.

It said the Covid-19 pandemic had accelerated interest in virtual or decentralised clinical trials, with more assessments being planned at home, and thus out of the clinic setting.

To date, there were just under 2,500 publications validating the company's 'CANTAB' cognitive assessments.

The company said that while CANTAB had been used for "many years" in clinics, with the assessment being overseen by clinical staff, use at home had been growing, supported by evidence showing that performance was comparable.

It said the clinical trial was aiming to use CANTAB to assess patients' cognition from their homes.

The trial was sponsored by an unnamed "leading pharmaceutical company" with a pipeline of central nervous system drugs that Cambridge Cognition said could benefit from cognitive assessments.

"We are delighted to have secured this contract and to be supporting another major pharmaceutical company to assess cognition in patients' homes," said chief executive officer Matthew Stork.

"This is a trend that we expect to continue and will therefore provide more growth opportunities for Cambridge Cognition in the future."

At 1229 BST, shares in Cambridge Cognition were up 20.81% at 119p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.